Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review

We report a case of a 43-year-old patient affected by GBM in treatment with regorafenib in third line of therapy with good disease control and long PFS.Case Rep Oncol 2022;15:642 –647
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research